Literature DB >> 19067762

Establishment and characterization of HER2-positive cell line derived from pleural effusion of human breast scirrhous carcinoma.

Isao Tabei1, Shigeki Nishiyama, Shigeo Yamashita, Hisashi Hashimoto, Toshiaki Tachibana, Ken Uchida, Hiroshi Ishikawa.   

Abstract

We have established a cell line derived from a pleural effusion of breast scirrhous carcinoma. This cell line presented immunohistochemically negative for estrogen receptor and slightly positive for progesterone receptor, and positive for c-erbB/HER2/neu. However the original tumor was found to be positive for estrogen receptor and progesterone receptor and slightly positive for c-erbB/HER2/neu expression. Enzyme and electrochemiluminescence immunoassays of tumor markers in the conditioned medium by the cell line revealed they secrete CA15-3, NCC-ST-439 and HER2 protein. We believe the cell line will contribute to the therapeutic study of malignant breast cancer.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19067762     DOI： 10.1111/j.1749-0774.2008.00056.x

Source DB:  PubMed          Journal:  Hum Cell        ISSN： 0914-7470            Impact factor:   4.374


  10 in total

1.  Establishment and characterization of a cell line (NABCA) derived from metastatic lymph nodes of breast scirrhous carcinoma.

Authors:  Satoshi Ohi; Shigeya Kyoda; Isao Tabei; Kouzou Ninomiya; Kayoko Sugiyama; Hisashi Hashimoto; Toshiaki Tachibana; Hiroshi Ishikawa
Journal:  Hum Cell       Date:  2006-11       Impact factor: 4.174

2.  neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.

Authors:  I L Andrulis; S B Bull; M E Blackstein; D Sutherland; C Mak; S Sidlofsky; K P Pritzker; R W Hartwick; W Hanna; L Lickley; R Wilkinson; A Qizilbash; U Ambus; M Lipa; H Weizel; A Katz; M Baida; S Mariz; G Stoik; P Dacamara; D Strongitharm; W Geddie; D McCready
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

Review 3.  Human breast carcinoma cells in continuous culture: a review.

Authors:  L W Engel; N A Young
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

4.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

5.  Establishment of epithelial cell line MDA-MB-157 from metastatic pleural effusion of human breast carcinoma.

Authors:  R K Young; R M Cailleau; B Mackay; W J Reeves
Journal:  In Vitro       Date:  1974 Jan-Feb

6.  The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.

Authors:  M D Pegram; R S Finn; K Arzoo; M Beryt; R J Pietras; D J Slamon
Journal:  Oncogene       Date:  1997-07-31       Impact factor: 9.867

7.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

8.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

9.  Glycosaminoglycans of normal and malignant cultured human mammary cells.

Authors:  E V Chandrasekaran; E A Davidson
Journal:  Cancer Res       Date:  1979-03       Impact factor: 12.701

Review 10.  The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review.

Authors:  P M Ravdin; G C Chamness
Journal:  Gene       Date:  1995-06-14       Impact factor: 3.688
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.